Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eton Pharmaceuticals (ETON) Gross Margin (2019 - 2025)

Eton Pharmaceuticals (ETON) has disclosed Gross Margin for 7 consecutive years, with 61.56% as the latest value for Q4 2025.

  • Quarterly Gross Margin rose 595.0% to 61.56% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 66.31% through Dec 2025, up 630.0% year-over-year, with the annual reading at 53.46% for FY2025, 655.0% down from the prior year.
  • Gross Margin hit 61.56% in Q4 2025 for Eton Pharmaceuticals, up from 34.97% in the prior quarter.
  • In the past five years, Gross Margin ranged from a high of 552.13% in Q1 2025 to a low of 12.18% in Q4 2023.
  • Historically, Gross Margin has averaged 87.65% across 5 years, with a median of 62.77% in 2024.
  • Biggest five-year swings in Gross Margin: crashed -720611bps in 2021 and later skyrocketed 48927bps in 2025.
  • Year by year, Gross Margin stood at 93.89% in 2021, then decreased by -20bps to 74.84% in 2022, then crashed by -84bps to 12.18% in 2023, then skyrocketed by 356bps to 55.6% in 2024, then increased by 11bps to 61.56% in 2025.
  • Business Quant data shows Gross Margin for ETON at 61.56% in Q4 2025, 34.97% in Q3 2025, and 63.0% in Q2 2025.